Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

TOKYO (Kyodo) -- A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan ...

In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Great Britain is the first country in Europe to approve amyloid inhibitor Kisunla (donanemab) and only the third to do so worldwide after the US and Japan. The decision not to provide NHS funding ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

Regarding donanemab, she indicates that there are certain differential ... For now, the medication has been approved in the ...

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch ... with the drug now launched in the US, Japan, and China, momentum is expected ...

The ministry intends to present its proposal to a government advisory council soon. All residents in Japan, regardless of their nationality, are required to pay into the national pension or ...

TOKYO: Japan's Prime Minister Shigeru Ishiba on Monday (Nov 11) faces a parliament vote expected to keep him in the job, but with a fragile grip on power after a disastrous general election.

Japan's Prime Minister Shigeru Ishiba speaks during a news conference at the prime minister's official residence in Tokyo, Japan, Nov 11, 2024. (Photo: Kiyoshi Ota/Pool via REUTERS) Shigeru Ishiba ...